SEC Form 4Coverage since Jul 30, 2026
$TRDA insider trading
Over the last 12 months, Entrada Therapeutics insiders reported no purchases and 2 sales totaling $1.6M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $1.6M 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $TRDA · 12Mvia TradingView
Top insiders · 12m
5AM Ventures V, L.P.—1× · $807K
PARMAR KUSH—1× · $807K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | 5AM Ventures V, L.P.10% | ▼ Sale | 116,474 | $6.93 | $807K | -3.9% | 2 tranches |
| Jul 31, 2026 | PARMAR KUSHD·10% | ▼ Sale | 116,474 | $6.93 | $807K | -3.9% | 2 tranches · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $TRDA feed.